SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two upcoming healthcare conferences in September.
| Cantor Global Healthcare Conference | ||
| Format: | Fireside chat and 1x1 meetings | |
| Date/time: | Wednesday, September 3 at 3:55 p.m. ET | |
| Location: | New York, NY | |
Morgan Stanley 23rd Annual Global Healthcare Conference | ||
| Format: | Fireside chat and 1x1 meetings | |
| Date/time: | Wednesday, September 10 at 10:45 a.m. ET | |
| Location: | New York, NY | |
The live and archived webcasts will be accessible from the company’s website at https://ir.structuretx.com/events-presentations/events and replays will be available for 90 days.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.
Investors:
Danielle Keatley
Structure Therapeutics Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Dan Budwick
1AB
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$33.47 |
| Daily Change: | 1.26 3.91 |
| Daily Volume: | 569,719 |
| Market Cap: | US$1.930B |
November 06, 2025 August 06, 2025 May 08, 2025 February 27, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
